OBESITY AND MULTIPLE-MYELOMA

被引:44
作者
FRIEDMAN, GD [1 ]
HERRINTON, LJ [1 ]
机构
[1] KAISER PERMANENTE MED CARE PROGRAM,DIV RES,OAKLAND,CA
关键词
BODY BUILD; MULTIPLE MYELOMA; OBESITY; USA;
D O I
10.1007/BF01694762
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An exploratory study was conducted of common clinical conditions as predictors of subsequent cancer in 143,574 outpatients of a health maintenance organization (in California, USA). An association was noted between obesity, diagnosed in 14,388 patients, and the subsequent development of multiple myeloma (MM) in up to 21 years (33 cases observed, 21.3 expected based on the experience of the entire cohort; standardized morbidity ratio = 1.55, 95 percent confidence interval [CI] = 1.06-2.17). This association was evaluated further in a second cohort of 163,561 multiphasic-checkup examines followed up for as many as 24 years. Body mass index (BMI) at entry examination was associated positively with the incidence of MM in White men (e.g., relative risk [RR] = 1.07, CI = 1.01-1.15 per unit increase in BMI; and RR = 1.68, CI = 0.75-3.78, comparing the highest with lowest quartile). This association was absent in White women, partially confirmed in Black men and women (BMI quartiles two, three, and four showed higher risk than quartile one), and not explained by the presence of diabetes mellitus. The association was reduced or absent with BMI based on reported greatest adult-weight, and in White women was inverse with BMI based on reported lowest adult-weight. Among subjects with more than one checkup, increased risk was associated directly with weight loss among White men and associated inversely with weight gain among Black women. These findings suggest that body build or nutritional status may be involved in the development of MM by mechanisms that are presently unknown. If increased weight is a causal factor, weight loss occurs later after the disease process begins.
引用
收藏
页码:479 / 483
页数:5
相关论文
共 12 条
[1]  
Kyle R.A., Plasma cell disorders, Cecil Textbook of Medicine, pp. 967-78, (1992)
[2]  
Riedel D.A., Pottern L.M., The epidemiology of multiple myeloma, Hematol Oncol Clin North Am, 6, pp. 225-47, (1992)
[3]  
Hiatt R.A., Friedman G.D., The frequency of kidney and urinary tract disease in a defined population, Kidney Int, 22, pp. 63-8, (1981)
[4]  
Krieger N., Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology, Am J Public Health, 82, pp. 703-10, (1992)
[5]  
Selby J.V., Friedman G.D., Fireman B.H., Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up, Cancer Res, 49, pp. 5736-47, (1989)
[6]  
Collen M.F., Davis L.F., The multitest laboratory in health care, J Occup Med, 11, pp. 355-60, (1969)
[7]  
Breslow N.E., Day N.E., Statistical Methods in Cancer Research. Vol. 2. The Design and Analysis of Cohort Studies, (1987)
[8]  
Harrell F.E., The PHLGM procedure, SUGI Supplemental Library User's Guide, pp. 437-66, (1986)
[9]  
Boffeta P., Stellman S.D., Garfinkel L., A case-control study of multiple myeloma nested in the American Cancer Society prospective study, International Journal of Cancer, 43, pp. 554-9, (1989)
[10]  
Chandra R.K., Nutrition and the immune system, Proc Nutr Soc, 52, pp. 77-84, (1993)